Coronaviruses cause severe diseases of the respiratory and gastrointestinal tract and the central nervous system in animals ([@bib0105]). Infection of humans with HCoV-OC43 and HCoV-229E are known since the 1960s to be associated with respiratory tract i.e. common cold diseases. Severe Acute Respiratory Syndrome-Coronavirus (SARS-CoV) is the most aggressive human agent, causing the lung disease SARS ([@bib0060]). HCoV-NL63 and HCoV-HKU1 were discovered in 2004 and 2005, respectively ([@bib0155], [@bib0180]). They cause upper and lower respiratory tract infections including bronchiolitis and pneumonia especially in young children, immunocompromised patients and the elderly ([@bib0150]).

Until now effective treatment of coronavirus infection in humans is unavailable ([@bib0125]), even though inhibitors of coronavirus enzymes (reviewed by ([@bib0140], [@bib0145]) and compounds inhibiting in vitro replication have been described ([@bib0090], [@bib0135], [@bib0160]). Coronaviruses represent the group of RNA viruses with the largest RNA genome known to date. Compared to other RNA viruses, the coronavirus polymerase has a rather low error frequency and may possess a RNA proof reading activity ([@bib0055]). However, the development of resistant mutants in the presence of drugs targeting coronaviral proteins remains a serious concern. Virus replication depends on a variety of host factors ([@bib0045], [@bib0165], [@bib0185]), which in turn represent potential antiviral targets. These might be more preferable targets than viral proteins as development of resistance is much less likely.

In a recent study we performed a genome-wide SARS-CoV yeast-two-hybrid interaction screen with human cDNA libraries identifying cyclophilins and FK506-binding proteins as interaction partners of SARS-CoV non-structural protein 1 (Nsp1). We identified Cyclosporin A (CsA) as a potent replication inhibitor of various human and animal CoVs ([@bib0110]). Inhibition of SARS-CoV, HCoV-229E and, in addition, of Mouse Hepatitis Virus was also confirmed by de Wilde et al. ([@bib0050]). Cyclophilins and FK506-binding proteins are collectively referred to as immunophilins because they bind the immunosuppressive drugs CsA and FK506, respectively. Furthermore, they share peptidyl-prolyl isomerase (PPIase) domains and chaperone functions facilitating protein folding ([@bib0040]). CsA was recently shown to exert inhibitory effects on herpes simplex virus, vaccinia virus ([@bib0035]), BK polyoma virus ([@bib0010]), human immunodeficiency virus 1 (HIV-1) ([@bib0025], [@bib0170]) and HCV ([@bib0070], [@bib0095], [@bib0175]). Whereas cyclophilins were reported to be required for replication of HIV-1 ([@bib0075]), vesicular stomatitis virus ([@bib0020]) and HCV ([@bib0100]), FK506-binding proteins were not found to play a role in the replication of HIV-1 ([@bib0025]) and HCV ([@bib0095], [@bib0175]). Orthopoxviruses are inhibited by FK506 ([@bib0120]).

FK506 was one of the first macrolides, discovered in 1984 in the bacterium *Streptomyces tsukubaensis*, with immunosuppressive activity. Although it is structurally unrelated to the cyclic undecapeptide CsA both molecules display similar properties of binding to the catalytic pocket of the PPIase domains of their cellular binding partners resulting in inhibition of their PPIase activities ([@bib0015]). Furthermore, the cyclophilin-CsA and FKBP-FK506 complexes bind to the cellular phosphatase calcineurin (CnA) which inhibits the dephosphorylation and activity of the nuclear factor of activated T-cells. The inhibition of this essential transcriptional regulator of important immune genes is the cause of immunosuppression. It is important to note that binding of the FKBP/FK506 complex to CnA, which is required for immunosuppression, and inhibition of PPIase activitiy, which is responsible for antiviral activity, are two independent mechanisms.

When studying the interaction of the SARS-CoV Nsp1 protein with cyclophilins A and B we discovered that replication of various coronaviruses is sensitive to CsA treatment including HCoV-NL63 and HCoV-229E ([@bib0110]). Since Nsp1 also interacted with FK506-binding proteins FKBP1A and FKBP1B, we examined in this study whether FK506 inhibits replication of human coronaviruses. In a first experiment VeroFM cells were infected with SARS-CoV at a multiplicity of infection (MOI) of 0.0001 in the presence of increasing concentrations of CsA and FK506. Virus RNA concentrations were measured after 24 h in supernatant of infected cells by real-time RT-PCR ([@bib0065]). Titers were reduced 128,740-fold by 33 μM CsA, and 11,112 fold by 49 μM FK506, respectively. [Fig. 1](#fig0005){ref-type="fig"}A shows the percentage of SARS-CoV inhibition under the influence of FK506, with an EC~50~ inhibitory concentration of about 6.9 μM. In [Fig. 1](#fig0005){ref-type="fig"}B the corresponding log~10~ titer reductions are represented.Fig. 1Effect of FK506 on SARS-CoV in VeroFM and on HCoV-NL63 replication in CaCo2 cells by qPCR (A--D) and plaque titration (E and F). Data shown are mean values of representative experiments performed in at least triplicates. Left *Y*-axes represent the percentage of reduction of virus replication in linear scale (A, C and E) and in log scale (B, D and F) at the indicated inhibitor concentrations, respectively. Percentage of cell viability with the mock-treated cells set to 100% are shown on the right *Y*-axes. FK506 concentrations used for each virus are given on the *X*-axis.

To examine whether FK506 exerts an inhibitory activity on other human coronaviruses, CaCo2 cells were infected with HCoV-NL63 at MOI = 0.004 ([@bib0080]) in the presence of increasing inhibitor concentrations. After two days RNA from cell culture supernatant was harvested and viral RNA was extracted using the High Pure Viral Nucleic Acid Kit (Roche) and quantified by real-time PCR using Superscript™ III One-Step Quantitative System with ROX (Invitrogen) allowing reverse transcription, cDNA synthesis and PCR amplification in a single step. PCR primers used were NL-63RF2 for 5′-CTTCTGGTGACGCTAGTACAGCTTAT-3′ (genome position nt 14459--14484) and NL-63RR2rev 5′-AGACGTCGTTGTAGATCCCTAACAT-3′ (genome position nt 14573--14597) and NL-63 probe was 5′-FAM-CAGGTTGCTTAGTGTCCCATCAGATTCAT-TAMRA-3′ (genome position nt 14532--14560). The EC~50~ inhibitory concentration for HCoV-NL63 was about 5.1 μM and replication was completely inhibited at 36 μM FK506 ([Fig. 1](#fig0005){ref-type="fig"}C), reflecting a 732-fold reduction of virus replication ([Fig. 1](#fig0005){ref-type="fig"}D). At this concentration cell viability (CellTiterGlo, Promega) was still about 75%. Inhibition of virus growth in CaCo2 cells was also confirmed by plaque titration assay ([@bib0080]) using serial virus dilutions in the presence of FK506 concentrations ranging from 0 μM to 24 μM. [Fig. 1](#fig0005){ref-type="fig"}E and F shows percentage and log reductions of inhibition of virus replication, respectively. Under the conditions of the plaque assay involving virus growth for four days, the decrease of virus titers occurred in a more linear fashion with an EC~50~ of about 13.4 μM (E). Complete inhibition was observed at 24 μM with a reduction by more than five orders of magnitude (F).

HCoV-229E viruses expressing Renilla luciferase ([@bib0110]) or GFP ([@bib0030]) reporter genes were used to examine the inhibitory effect of FK506. HuH7 cells were infected with MOI = 0.1 and incubated for two days in the presence of increasing concentrations of FK506 in the culture medium. Viral replication was determined by measuring Renilla luciferase activity. [Fig. 2](#fig0010){ref-type="fig"}A and B shows percent and Log reductions of virus growth, respectively. About 5.4 μM FK506 were found to be effective as an EC~50~ for HCoV-229E-luc. Cell viability was reduced to about 70% (at 24 μM) as compared to untreated cells, indicating that virus reduction was due to the drug but not to cell death. [Fig. 2](#fig0010){ref-type="fig"}C and D shows a microscopic comparison of HCoV-229E-GFP infection under increasing concentrations of CsA and FK506. Reduction of virus infection was quantified by determining fluorescence intensity from microscope images of infected Huh7 cells. The pictures were analysed by using the software ImageJ 1.44 ([@bib0005], [@bib0115]). The integrated density for three different regions of interest was measured in each picture and the obtained averages were used to calculate correlates of virus replication efficiency. The determined EC~50~ was 12.2 μM for FK506 under these conditions. GFP fluorescence was inversely correlated to inhibitor concentration, with DAPI staining of cell nuclei indicating confluence of HuH7 cells and equivalent cell densities at all concentration steps. Virus growth was completely abolished between concentration of 8--12 μM CsA and 18--25 μM FK506. The latter correlates well with the inhibitory concentration determined for HCoV-229E-luc. For both HCoV-229E and HCoV-NL63, EC~50~ values were higher in plaque and GFP titrations as compared to direct replication assays by either RT-PCR or luciferase measurement. However, deviations between both assay formats were only by factors of 3.2 (HCoV-NL63) and 2.6 (HCoV-229E).Fig. 2Effect of FK506 on HCoV-229E-LUC replication in HuH7 cells by Renilla activity measurement (A and B) and on HCoV-229E-GFP by quantification of GFP fluorescence (C and D). Data shown are mean values (RLU) of a representative experiment performed in triplicate. The left *Y*-axis represents the percentage of reduction of virus replication in linear scale (A) and in log scale (B), respectively, at the indicated inhibitor concentrations given on the *X*-axis. Percentage of cell viability with the mock-treated cells set to 100% are shown on the right *Y*-axis (A). Virus reduction values in log scale are given on the *Y*-axis of (B). Quantification of GFP fluorescence was used as a semiquantitative measure of virus reduction at the indicated inhibitor concentrations (C and D).

In order to examine whether the cellular FK506-binding proteins FKBP1A and FKBP1B are required for virus replication, CaCo2 knockdown cell lines were established using lentiviral expression of shRNA (Sirion GmbH, Martinsried, Germany). Cells were transduced at MOI 30 with MISSIONTM lentiviral non-target control, cyclophilin B (PPIB), FKBP1A, or FKBP1B shRNA lentiviruses. Sequences used for gene knockdown are listed in [Table 1](#tbl0005){ref-type="table"}A. Stable shRNA-expressing cells were generated through 3 weeks of bulk-selection in 10--15 μg/ml puromycin-containing medium (DMEM + 10% FCS + 2 mM [l]{.smallcaps}-glutamine + 1 mM Na-pyruvate). The high puromycin concentration needed for selection of CaCo2 cells might result from an enhanced expression of *MDR-1* (multi drug resistant protein 1 gene) depleting cells very efficiently from inhibitory drug molecules ([@bib0130]). From the bulk-selected knockdown and control cells mRNA expression was quantified by real-time RT-PCR. For reverse transcription 1 μg of total RNA was used. Amplification products were detected by SYBR I, and amplicon integrity was verified by melting point analysis. Cyclophilin A (PPIA) served as a reference gene against PPIB to determine the specificity of the knockdown. mRNA expression levels of PPIB, FKBP1A, and FKBP1B were then determined by real-time RT-PCR with primers listed in [Table 1](#tbl0005){ref-type="table"}B. [Fig. 3](#fig0015){ref-type="fig"}A shows PPIB, FKBP1A and FKBP1B mRNA expression in bulk-selected CaCo2 cells. In comparison to non-target controls a 98% and 96% knockdown was determined for PPIB and FKBP1A/1B, respectively.Table 1Particle setTargetshRNA sequence (5′ → 3′)(A) shRNA sequences used for lentiviral-based gene knockdownNon-target control\
TRC1.5 Vector (pLKO.1-puro)CCGGCAACAAGATGAAGAGCACCAACTCGAGTTGGTGCTCTTCATCTTGTTGTTTTTGPPIB: SHVRS-NM_000942TRCN000049251CCGGGTTCTTCATCACGACAGTCAACTCGAGTTGACTGTCGTGATGAAGAACTTTTTGFKBP1A: SHVRS-NM_054014TRCN0000005951CCGGGCCAAACTGACTATATCTCCACTCGAGTGGAGATATAGTCAGTTTGGCTTTTTFKBP1B: SHVRS-NM_004116TRCN00000151663CCGGGAAGTTTGATTCATCCAGAGACTCGAGTCTCTGGATGAATCAAACTTCTTTTTTGqRT-PCR primerSequence (5′ → 3′)(B) Sequences of primers used for quantification of gene knockdownhPPIB_FCTCTCCGAACGCAACATGAAGhPPIB_RACCTTGACGGTGACTTTGGGh_FKBP1A_FCACTACACCGGGATGCTTGAAh_FKBP1A_RTTCTTCCCAGCCTCGGATCAh_FKBPB_FGCAGGAAGGAACTCAAGGTGh_FKBP1B_RAGCAACTTGGGCAGAGAGAAFig. 3Growth of HCoV-NL63 on CaCo2-ΔPPIB, -ΔFKBP1A, -ΔFKBP1B knockdown mutant cells. Knockdown of gene expression was analysed by qPCR (A). Virus growth was tested by plaque titration on the knockdown cells (B).

Plaque titration showed that HCoV-NL63 grew to similar titers in CaCo2 wild type (not shown), CaCo2 shRNA control and CaCo2-ΔPPIB knockdown cells indicating that expression of PPIB was not necessary for viral growth. Conversely, knockdown of FKBP1ΔA/B did not result in any plaque formation, identifying FKBP1A/B products as key proteins required for viral replication. Similarly, real-time PCR amplification of RNA genomes in the supernatant of the HCoV-NL63-infected cell lines showed significantly reduced titers in the CaCo2-ΔFKBP1A knockdown cells as compared to CaCo2sh and CaCo2-ΔPPIB knockdown cells (not shown), confirming the results of the plaque titrations.

In summary, FK506 inhibits the replication of SARS-CoV, HCoV-NL63 and HCoV-229E at non-toxic, low-micromolar concentrations with a reduction of virus titers by several orders of magnitude to undetectable levels. In a comparative study of the effect of CsA and FK506 on HIV-1, the former inhibited virus replication completely (IC~50~: 1--2 μg/ml) whereas latter had an inhibitory effect on chronically but not on newly infected cells \[up to 10 μg/ml FK506 ([@bib0025])\]. Also in the case of HCV, FK506 had no effect on the replication of replicon RNA up to concentrations of 3 μg/ml ([@bib0175]). Considering the higher drug concentrations of CsA and FK506 needed for inhibition of coronavirus replication it can be speculated that also HIV-1 and HCV might be inhibited by higher FK506 concentrations. It also remains to be clarified why the low nanomolar affinities of FKBP1A/B to FK506 do not reflect the EC50 inhibitory concentrations of coronaviruses which reside in the low micromolar range. This might be explained by a stronger affinity of coronavirus proteins to the cellular proteins as compared to FK506.

Lack of growth of HCoV-NL63 in stable CaCo2-ΔFKBP1A and -ΔFKBP1B, but not -ΔPPIB knockdown mutants indicates the requirement of FKBP1A and FKBP1B for HCoV-NL63 replication. As the two proteins share about 83% homology on the amino acid level (not shown) they do not substitute for each other upon individual knockdown. A common structural feature of FKBP proteins is the PPIase domain, also called FK506-binding domain. Its peptidylprolyl *cis*/*trans* isomerase activity influences cellular pathways by binding to cellular proteins ([@bib0085]). These activities are common to many FKBP family members containing a PPIase domain and separate chaperone functions can be discriminated from them ([@bib0015]).

The two less pathogenic coronaviruses HCoV-NL63 and HCoV-229E and the highly pathogenic SARS-CoV are sensitive to CsA and FK506, indicating the involvement of cyclophilins and FK506-binding proteins in viral replication. However, it is not clear what functions of these cellular proteins are required for virus replication. For SARS-CoV we have shown that Nsp1 binds to cyclophilins and to FKBP1A and FKBP1B by Y2H and Lumier assay ([@bib0110]). Also, Nsp1 proteins of HCoV-NL63 and -229E interact with FKBP1A and FKBP1B in Y2H (not shown). The mechanism and function of these interactions have to be analysed in more detail. Furthermore it has to be clarified whether other viral proteins are involved in the relation of coronaviruses and immunophilins.
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